Welcome to our dedicated page for STANDARD BIOTOOLS news (Ticker: LAB), a resource for investors and traders seeking the latest updates and insights on STANDARD BIOTOOLS stock.
Standard BioTools Inc. (LAB) pioneers precision tools for accelerating biomedical discoveries in proteomics and genomics. This dedicated news hub provides investors, researchers, and industry professionals with comprehensive updates on the company's advancements in mass cytometry, microfluidics, and high-throughput research solutions.
Access real-time press releases, earnings reports, and strategic announcements to stay informed about LAB's innovations in life sciences technology. Our curated collection includes updates on product launches, clinical research collaborations, and scientific milestones that shape the future of translational medicine.
Key content categories cover financial performance, technology partnerships, and regulatory developments, alongside insights into applications across oncology, immunology, and biomarker discovery. Each update is verified for accuracy and relevance, ensuring you receive authoritative information directly impacting biomedical research trends.
Bookmark this page for streamlined access to Standard BioTools' latest progress in developing automated, sample-efficient platforms trusted by leading academic institutions and pharmaceutical organizations worldwide.
Standard BioTools Inc. (Nasdaq:LAB) announced it will report its first quarter 2023 financial results on May 9, 2023, after market close. The company's management will host a conference call at 2:00 p.m. PT (5:00 p.m. ET) on the same day to discuss the results and operational developments. A press release will precede the call.
The company, focused on providing innovative tools for biomedical research, leverages proprietary technologies to enhance research capabilities in oncology and immunotherapy. They aim to improve patient outcomes through their advanced mass cytometry and microfluidics technologies.
Standard BioTools Inc. (Nasdaq:LAB) announced equity awards for new employees as part of its 2022 Inducement Equity Incentive Plan on April 20, 2023. The Compensation Committee granted awards to four individuals, comprised of 43,700 restricted stock units (RSUs) and stock options to purchase 400,000 shares. The RSUs will vest in stages starting from February 20, 2024, while the stock options have a 10-year term with an exercise price of $1.76, beginning to vest on May 20, 2024. The awards are intended to attract talent and comply with Nasdaq Listing Rule 5635(c)(4). Standard BioTools aims to enhance human health through innovative technologies in the biomedical research sector.
Standard BioTools Inc. (Nasdaq:LAB) has launched the Hyperion XTi™ Imaging System at the AACR meeting in Orlando, aimed at advancing clinical research. This next-generation system enhances spatial biology studies by detecting single-cell data five times faster than previous models, allowing researchers to process up to 40 slides daily. Powered by Imaging Mass Cytometry™ (IMC™), the Hyperion XTi can reliably identify over 40 biomarkers from any tissue sample without autofluorescence interference. It features a straightforward workflow and enables the simultaneous detection of protein and RNA. The new system is currently in production with initial orders expected to ship this quarter, with the company asserting its potential to expedite drug development and immuno-oncology research.
Standard BioTools Inc. (Nasdaq:LAB) announced the granting of equity awards to an incoming employee as a material inducement under its 2022 Inducement Equity Incentive Plan. The awards include nonstatutory stock options for 647,112 shares at an exercise price of $3.99, and 112,293 restricted stock units (RSUs). The RSUs will vest over four years, with 25% vesting on April 4, 2023, and the rest annually thereafter. The stock options have a 10-year term and also vest over four years. The equity awards comply with Nasdaq Listing Rule 5635(c)(4), ensuring governance standards are maintained.
Standard BioTools Inc. (Nasdaq:LAB) announced the appointment of Fenel Eloi to its Board of Directors on March 15, 2023. Eloi brings over 12 years of experience from Cell Signaling Technology, where he led significant business growth and global transformations. He will also participate in the Board's Audit Committee. This appointment coincides with the retirement of Bill Colston from the Board. CEO Michael Egholm expressed confidence in Eloi's leadership as the company advances its mission to enhance human health through innovative life science technologies.
Standard BioTools Inc. (Nasdaq:LAB) announced that CEO Michael Egholm will join a fireside chat at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 21, 2023, at 3:00 p.m. ET. The event aims to discuss the company's role in advancing human health through innovative technologies. The presentation will be webcast live, with an archived recording available on the company's Investor Relations page. Standard BioTools specializes in mass cytometry and microfluidics technologies, aiding in the swift development of medicines and better patient outcomes.
